What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.”In the company’s words, NCT06580301 on ClinicalTrials.gov
- Tested for
- Primary Membranous Nephropathy (2 trials), B-cell Acute Lymphoblastic Leukemia, Systemic Lupus Erythematosus (SLE), Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Main trialPhase 1/2
- “The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).”In the company’s words, NCT06580301 on ClinicalTrials.gov
Other drugs for Primary Membranous Nephropathy
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- BelzutifanMerck & Co. · Phase 3
- AbexinostatXynomic Pharmaceuticals, Inc. · Phase 3
Coming up5
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Oct 2028Phase 1 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2026 | Study of YK012 in B-cell Acute Lymphoblastic Leukemia | |
| Phase 1/2Recruiting | Jun 2027 | Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus | |
| Phase 1Recruiting | Dec 2026 | Study of YK012 in Primary Membranous Nephropathy | |
| Phase 1Not yet recruiting | Oct 2028 | A Phase I Study of YK012 in Primary Membranous Nephropathy | |
| Phase 1Recruiting | Dec 2028 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026